nach oben

Erschienen in:

04.01.2022 | Original Article

Empagliflozin Ameliorates Ouabain-Induced Na⁺ and Ca²⁺ Dysregulations in Ventricular Myocytes in an Na⁺-Dependent Manner

verfasst von: Xiaodong Peng, Linling Li, Rong Lin, Xuesi Wang, Xinmeng Liu, Yukun Li, Changsheng Ma, Yanfei Ruan, Nian Liu

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of glucose-lowering agents that have improved clinical outcomes in patients with heart failure; however, their therapeutic mechanisms remain elusive. Although contradictory results have been reported, it has been proposed that improving Na⁺ homeostasis may be the underlying mechanism of action of SGLT2 inhibitors in heart failure treatment. This study explored whether empagliflozin ameliorates Na⁺ and Ca²⁺ handling disorders induced by ouabain in an Na⁺-dependent manner.

Methods

Isolated ventricular myocytes of mice were incubated with ouabain to establish a cellular model of Na⁺ overload. Effects of empagliflozin on Na⁺ and Ca²⁺ handling were evaluated using an ionOptix system and a confocal microscope. Distinct cytosolic Na⁺ levels were established by incubating different ouabain concentrations (10, 50, and 100 μmol/L).

Results

In the absence of ouabain, 1 μmol/L empagliflozin had a negligible impact on Na⁺ and Ca²⁺ handling in ventricular myocytes. Ouabain (50 μmol/L) significantly enhanced cytosolic Na⁺ levels and dysregulated Ca²⁺ handling, including an increased Ca²⁺ transient amplitude, elevated Ca²⁺ content in the sarcoplasmic reticulum, and enhanced spontaneous Ca²⁺ release normalized by treatment with 1 μmol/L empagliflozin within 10 min. All Na⁺ and Ca²⁺ handling abnormalities induced by ouabain were reversed by 1 μmol/L empagliflozin. The efficacy of empagliflozin was more potent at higher cytosolic Na⁺ levels. Pretreatment with the Na⁺/H⁺ exchanger (NHE) inhibitor (1 μmol/L cariporide) abolished the effects of empagliflozin.

Conclusion

Empagliflozin ameliorates ouabain-induced Na⁺ and Ca²⁺ handling disorders in a cytosolic Na⁺-dependent manner, potentially by inhibiting the NHE.

Nur mit Berechtigung zugänglich

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.CrossRefPubMed

Barbarawi M, Al-Abdouh A, Barbarawi O, Lakshman H, Chen K: SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart failure reviews 2021:1–10.

Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243–55.CrossRefPubMed

Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Therapy. 2010;1(2):57–92.CrossRefPubMedPubMedCentral

Baartscheer A, Schumacher CA, Wüst RC, Fiolet JW, Stienen GJ, Coronel R, Zuurbier CJ. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017;60(3):568–73.CrossRefPubMed

Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. Basic to Translational Science. 2020;5(6):632–44.CrossRefPubMedPubMedCentral

Feng J, Armillei MK, Yu AS, Liang BT, Runnels LW, Yue L: Ca(2+) signaling in cardiac fibroblasts and fibrosis-associated heart diseases. J Cardiovasc Dev Dis 2019, 6(4).

Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia. 2018;61(3):722–6.CrossRefPubMed

Zhang H, Uthman L, Bakker D, Sari S, Chen S, Hollmann MW, Coronel R, Weber NC, Houten SM, van Weeghel M, et al. Empagliflozin decreases lactate generation in an NHE-1 dependent fashion and increases α-ketoglutarate synthesis from palmitate in type II diabetic mouse hearts. Front Cardiovasc Med. 2020;7:592233.CrossRefPubMedPubMedCentral

10.

Trum M, Riechel J, Lebek S, Pabel S, Sossalla ST, Hirt S, Arzt M, Maier LS, Wagner S: Empagliflozin inhibits Na+/H+ exchanger activity in human atrial cardiomyocytes. ESC heart failure 2020.

11.

Chung YJ, Park KC, Tokar S, Eykyn TR, Fuller W, Pavlovic D, Swietach P, Shattock MJ: Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+] i in the heart. Cardiovascular research 2020.

12.

Jiang L, Li L, Ruan Y, Zuo S, Wu X, Zhao Q, Xing Y, Zhao X, Xia S, Bai R. Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium. Heart Rhythm. 2019;16(9):1374–82.CrossRefPubMed

13.

Wu K, Li L-L, Li Y-K, Peng X-D, Zhang M-X, Liu K-S, Wang X-S, Yang J-X, Wen S-N, Ruan Y-F, et al. Modifications of the Langendorff method for simultaneous isolation of atrial and ventricular myocytes from adult mice. JoVE. 2021;171:e62514.

14.

Abràmoff MD, Magalhães PJ, Ram SJ. Image processing with ImageJ. Biophotonics international. 2004;11(7):36–42.

15.

Despa S. Myocyte [Na+] I dysregulation in heart failure and diabetic cardiomyopathy. Front Physiol. 2018;9:1303.CrossRefPubMedPubMedCentral

16.

Packer M. Reconceptualization of the molecular mechanism by which sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure events. Circulation. 2019;140(6):443–5.CrossRefPubMed

17.

Pieske B, Houser SR. [Na+] i handling in the failing human heart. Cardiovasc Res. 2003;57(4):874–86.CrossRefPubMed

18.

Mustroph J, Wagemann O, Lücht CM, Trum M, Hammer KP, Sag CM, Lebek S, Tarnowski D, Reinders J, Perbellini F. Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC heart failure. 2018;5(4):642–8.CrossRefPubMedPubMedCentral

19.

Philippaert K, Kalyaanamoorthy S, Fatehi M, Long W, Soni S, Byrne NJ, Barr A, Singh J, Wong J, Palechuk T. Cardiac late sodium channel current is a molecular target for the sodium/glucose cotransporter 2 inhibitor empagliflozin. Circulation. 2021;143(22):2188–204.CrossRefPubMedPubMedCentral

20.

Hamouda N, Sydorenko V, Qureshi M, Alkaabi J, Oz M, Howarth F. Dapagliflozin reduces the amplitude of shortening and Ca 2+ transient in ventricular myocytes from streptozotocin-induced diabetic rats. Mol Cell Biochem. 2015;400(1):57–68.CrossRefPubMed

21.

Yurista SR, Silljé HH, Oberdorf-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, van Goor H, van Veldhuisen DJ, de Boer RA, Westenbrink BD. Sodium–glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. 2019;21(7):862–73.CrossRefPubMed

22.

Keul P, van Borren MM, Ghanem A, Müller FU, Baartscheer A, Verkerk AO, Stümpel F, Schulte JS, Hamdani N, Linke WA. Sphingosine-1-phosphate receptor 1 regulates cardiac function by modulating Ca2+ sensitivity and Na+/H+ exchange and mediates protection by ischemic preconditioning. J Am Heart Assoc. 2016;5(5):e003393.CrossRefPubMedPubMedCentral

23.

Butler J, Usman MS, Khan MS, Greene SJ, Friede T, Vaduganathan M, Filippatos G, Coats AJS, Anker SD. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC heart failure. 2020;7(6):3298–309.CrossRefPubMedPubMedCentral

24.

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M. Brunner–La Rocca H-P, Choi D-J, Chopra V, Chuquiure-Valenzuela E: Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.CrossRefPubMed

25.

Requena-Ibáñez JA, Santos-Gallego CG, Rodriguez-Cordero A, Vargas-Delgado AP, Mancini D, Sartori S, Atallah-Lajam F, Giannarelli C, Macaluso F, Lala A. Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study. Heart Failure. 2021;9(8):578–89.PubMed

26.

Pabel S, Wagner S, Bollenberg H, Bengel P, Kovacs A, Schach C, Tirilomis P, Mustroph J, Renner A, Gummert J. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018;20(12):1690–700.CrossRefPubMed

27.

Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Garcia-Ropero A, Ishikawa K, Watanabe S, Picatoste B, Vargas-Delgado AP, Flores-Umanzor EJ, Sanz J: Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis/stiffness in nondiabetic heart failure: a multimodality study. JACC: Cardiovasc Imaging 2021, 14(2):393–407.

28.

Theroux P, Chaitman B, Danchin N, Erhardt L, Meinertz T, Schroeder J, Tognoni G, White H, Willerson J, Jessel A. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations: main results of the GUARDIAN trial. Circulation. 2000;102(25):3032–8.CrossRefPubMed

Titel: Empagliflozin Ameliorates Ouabain-Induced Na+ and Ca2+ Dysregulations in Ventricular Myocytes in an Na+-Dependent Manner
verfasst von: Xiaodong Peng
Linling Li
Rong Lin
Xuesi Wang
Xinmeng Liu
Yukun Li
Changsheng Ma
Yanfei Ruan
Nian Liu
Publikationsdatum: 04.01.2022
Verlag: Springer US
Erschienen in: Cardiovascular Drugs and Therapy / Ausgabe 3/2023
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-021-07311-x

Neu im Fachgebiet Kardiologie

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Model-Based Risk Prediction of Rivaroxaban with Amiodarone for Moderate Renal Impaired Elderly Population

Sacubitril/Valsartan Can Reduce Atrial Fibrillation Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation

When Is It Appropriate to Publish a Meta-Analysis in Cardiovascular Drugs and Therapy?

Flavopiridol Mitigates the Progression of Monocrotaline-Induced Pulmonary Hypertension in Rats by Targeting Cyclin-Dependent Kinase 9